{
    "guideline": {
        "id": "PA166265201",
        "name": "Annotation of DPWG Guideline for oxcarbazepine and HLA-B",
        "source": "DPWG",
        "version": 7,
        "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166265201",
        "relatedChemicals": [
            {
                "id": "PA450732",
                "name": "oxcarbazepine",
                "symbol": null
            }
        ],
        "relatedGenes": [
            {
                "id": "PA35056",
                "name": "major histocompatibility complex, class I, B",
                "symbol": "HLA-B"
            }
        ],
        "recommendation": true
    },
    "recommendations": [
        {
            "id": "PA166299118",
            "name": "Recommendation PA166299118",
            "population": null,
            "classification": {
                "term": "N/A",
                "termId": "guidelineStrength:981501929"
            },
            "relatedChemicals": [
                {
                    "id": "PA450732",
                    "name": "oxcarbazepine",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452061481,
                "html": "<ul>\n<li>Carefully weigh the risk of SJS against the benefits.</li>\n<li>Avoid oxcarbazepine if an alternative is available.\n<ul>\n<li>Carbamazepine carries a 10-fold higher risk of SJS/TEN in these patients and is therefore not an alternative.</li>\n<li>In these patients, phenytoin and lamotrigine carry a similar risk of SJS/TEN as oxcarbazepine, but more severe forms of SJS/TEN (SJS/TEN overlap and TEN) are also\nobserved with these medicines. Therefore, they are also not suitable as alternatives.</li>\n</ul>\n</li>\n<li>If it is not possible to avoid oxcarbazepine, advise the patient to report any rash immediately</li>\n</ul>\n"
            },
            "implications": [
                "Stevens-Johnson syndrome, the severe cutaneous side effect that can potentially result in permanent damage, occurs more often in patients with this genetic variation. The calculated risk of oxcarbazepine-induced SJS in patients with HLA-B*1502 is 0.73%."
            ],
            "lookupKey": {
                "HLA-B": "*15:02 positive"
            },
            "dosingInformation": false,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": true,
            "guidanceLevel": "3"
        }
    ],
    "citations": [],
    "version": "2024-03-25-16-13"
}